Home Angiogenesis Bcr-Abl inhibitor Vodobatinib (K0706)

research use only

Vodobatinib (K0706) Bcr-Abl inhibitor

Cat.No.E0047

Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. It exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM, 165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H, BCR-ABL1E255V and BCR-ABL1T315I, respectively.
Vodobatinib (K0706) Bcr-Abl inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 453.92

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: E004701 DMSO]91 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.71%
99.71

Chemical Information, Storage & Stability

Molecular Weight 453.92 Formula

C27H20ClN3O2

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1388803-90-4 -- Storage of Stock Solutions

Synonyms SCO-088, SUN K706, SUN-K0706 Smiles CC1=C(C=C(C=C1)C(=O)NNC(=O)C2=C(C)C=CC=C2Cl)C#CC3=CC4=CC=CC=C4N=C3

Solubility

In vitro
Batch:

DMSO : 91 mg/mL (200.47 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
BCR-ABL1 [1]
7 nM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03655236 Active not recruiting
Early Parkinson Disease
Sun Pharma Advanced Research Company Limited
 February 18 2019 Phase 2
NCT02629692 Active not recruiting
Healthy (For Part A)|Chronic Myeloid Leukemia (for Part B and C)
Sun Pharma Advanced Research Company Limited
 April 25 2017 Phase 1|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map